Page 1 of 1

MS drug Fampyra receives negative opinion from the CHMP

Posted: Fri Jan 21, 2011 5:04 am
by MSUK
Image

Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.

Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310

Re: MS drug Fampyra receives negative opinion from the CHMP

Posted: Fri Jan 21, 2011 10:25 am
by scorpion
squiffy2 wrote:Image

Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.

Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
It just seems that no one can make up their minds about amprya. Usually this means that it is not living up to expectations and will slowly fizzle out! :cry:

Walking speed

Posted: Sat Jan 22, 2011 1:11 am
by RuSmolikova
Walking speed is not meaningful benefit for european regulator...
<shortened url>